Dianthus Therapeutics, Inc.
NASDAQ:DNTHBiotechnology
-$1.03 today
- Market cap
- $4.73B
- Beta
- 0.07
- P/E (TTM)
- -343.0
- EPS (TTM)
- -$0.24
Volume 0.84M
Average 0.82M
DNTH Net Income
Bottom-line profit after all expenses, interest, and taxes.
Dianthus Therapeutics, Inc.NASDAQ: DNTH
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income remains negative
Q2 FY2026 net income was -$50.22M, compared with -$31.63M a year earlier. Trailing-twelve-month net income was -$29.91M.
Context
- Net income amounted to 7973.3% of revenue in FY2025, up 6610.6 pp from a year earlier.
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 11 analysts of -$133.27M (+17.9%) for the fiscal year ending Dec 2026, a step up from the -91.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$50.22M-23.0% QoQ
- Last fiscal yearDec 2025
- -$162.34M-91.1% YoY
- LTMJun 2026
- -$29.91M+73.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -58.8% | -47.3% | +11.4 pp |
| 1 year | -91.1% | +17.9% | +109.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (162.34M) USD
- Year-over-year change
- -91.1%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (162.34M) | -91.1% |
| FY2024 | 2024-12-31 | (84.97M) | -95.1% |
| FY2023 | 2023-12-31 | (43.56M) | -53.0% |
| FY2022 | 2022-12-31 | (28.48M) | -117.2% |
| FY2021 | 2021-12-31 | (13.11M) | — |
Net Income vs competitors
How DNTH compares with its peers on the latest reported figures
- DNTH's LTM Jun 2026 net income of -$29.91M is the 3rd highest of the 10 companies compared; the peer median is -$151.77M.
- Its year-over-year change of +73.9% is the 3rd highest of 10, against a peer median of -77.0%.
- Net income amounts to 1570.9% of revenue for DNTH, versus a peer median of 6553.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $33.24M | +155.6% | — | 61.9% | |
| LTM Mar 2026 | -$26.79M | +81.0% | — | 11.5% | |
| LTM Jun 2026 | -$29.91M | +73.9% | — | 1570.9% | |
| FY2025 | -$55.48M | -255.0% | — | 86687.5% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | -$87.07M | -34.3% | — | — |
| LTM Mar 2026 | -$151.77M | -296.2% | — | 8550.6% | |
| LTM Mar 2026 | -$257.08M | -77.0% | — | — | |
| LTM Jun 2026 | -$401.9M | -84.1% | — | — | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | -$438.96M | -92.9% | — | 5933.5% |
| LTM Sep 2026 | -$508.96M | -9.5% | — | 7173.5% | |
| Peer median (excluding DNTH) | -$151.77M | -77.0% | — | 6553.5% | |
Competitors are the stored peer set for DNTH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.48M | 6.42M | 2.83M | 6.24M | 2.04M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 1.48M | 6.42M | 2.83M | 6.24M | 2.04M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 12.61M | 29.38M | 32.84M | 83.11M | 145.64M |
| Selling, General & Admin | 1.96M | 6.74M | 18.16M | 24.99M | 34.33M |
| Operating Expenses | 14.56M | 36.12M | 51M | 108.1M | 179.97M |
| Depreciation & Amortization | 2.02M | 147K | 355K | 412K | 428K |
| EBITDA | (11.09M) | (28.33M) | (43.2M) | (84.56M) | (161.91M) |
| EBITDA Margin | -751.3% | -441.5% | -1528.7% | -1356.2% | -7952.3% |
| Operating Income | (13.09M) | (29.71M) | (48.17M) | (101.86M) | (177.93M) |
| Operating Margin | -886.6% | -462.9% | -1704.7% | -1633.7% | -8739.3% |
| Interest Income | 100K | 1.15M | 4.76M | 17.37M | 16.12M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (23K) | 1.23M | 4.62M | 16.9M | 15.6M |
| Income Before Tax | (13.11M) | (28.48M) | (43.56M) | (84.97M) | (162.34M) |
| Pre-Tax Margin | -888.1% | -443.8% | -1541.2% | -1362.8% | -7973.3% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (13.11M) | (28.48M) | (43.56M) | (84.97M) | (162.34M) |
| Net Margin | -888.1% | -443.8% | -1541.2% | -1362.8% | -7973.3% |
| EPS (Basic) | (3.82) | (7.60) | (8.45) | (2.55) | (4.20) |
| EPS (Diluted) | (3.82) | (7.60) | (8.45) | (2.55) | (4.20) |
| Weighted Avg Shares | 3.43M | 3.75M | 5.15M | 33.31M | 37.79M |
| Weighted Avg Shares (Diluted) | 3.43M | 3.75M | 5.15M | 33.31M | 37.79M |
Dianthus Therapeutics, Inc.
NASDAQ:DNTH
Intrinsic Alpha fair value
Locked
Current Price
$83.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.